"CD56 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
| Descriptor ID |
D019002
|
| MeSH Number(s) |
D12.776.395.550.200.250.520.156 D12.776.543.550.200.250.520.156 D23.050.301.264.894.156 D23.050.301.350.250.520.156 D23.101.100.894.156
|
| Concept/Terms |
CD56 Antigen- CD56 Antigen
- Antigen, CD56
- Leu-19 Antigen
- Antigen, Leu-19
- Leu 19 Antigen
- Antigens, CD56
- NKH-1 Antigen
- Antigen, NKH-1
- NKH 1 Antigen
- CD56 Antigens
|
Below are MeSH descriptors whose meaning is more general than "CD56 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Cell Adhesion Molecules [D12.776.395.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.395.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.395.550.200.250.520]
- CD56 Antigen [D12.776.395.550.200.250.520.156]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Cell Adhesion Molecules [D12.776.543.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.543.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.543.550.200.250.520]
- CD56 Antigen [D12.776.543.550.200.250.520.156]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD56 Antigen [D23.050.301.264.894.156]
- Cell Adhesion Molecules [D23.050.301.350]
- Cell Adhesion Molecules, Neuronal [D23.050.301.350.250]
- Neural Cell Adhesion Molecules [D23.050.301.350.250.520]
- CD56 Antigen [D23.050.301.350.250.520.156]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD56 Antigen [D23.101.100.894.156]
Below are MeSH descriptors whose meaning is more specific than "CD56 Antigen".
This graph shows the total number of publications written about "CD56 Antigen" by people in this website by year, and whether "CD56 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD56 Antigen" by people in Profiles.
-
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun. 2021 08 11; 12(1):4854.
-
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol. 2021 07; 34(7):1358-1366.
-
Pooled Sequencing of Candidate Genes Implicates Rare Variants in the Development of Asthma Following Severe RSV Bronchiolitis in Infancy. PLoS One. 2015; 10(11):e0142649.
-
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant. 2008 Mar; 14(3):290-300.
-
CD4+ CD56+ hematodermic neoplasm. Am J Dermatopathol. 2007 Feb; 29(1):59-61.
-
Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med. 2007; 35(3):407-14.
-
P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiol Dis. 2005 Dec; 20(3):969-85.
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
-
Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol. 2002 Feb; 117(2):306-13.
-
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001 Jun 01; 97(11):3574-80.